# NovaBridge Biosciences: Form 20-F for the period ended Dec 31, 2024

- Company: [NovaBridge Biosciences](/companies/nbp.md) (CIK 1778016)
- Form: 20-F
- Filed: 2025-04-03
- Accepted by EDGAR: Apr 3, 2025, 16:01 ET
- Period: 2024-12-31
- Accession: 0000950170-25-050344
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1778016/000095017025050344/imab-20241231.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1778016/000095017025050344/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 12 months, 2024-01-01 to 2024-12-31 | $21.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months, 2024-01-01 to 2024-12-31 | −$51.4m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months, 2024-01-01 to 2024-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months, 2024-01-01 to 2024-12-31 | −$22.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2024-01-01 to 2024-12-31 | −$0.12 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months, 2024-01-01 to 2024-12-31 | −$0.12 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months, 2024-01-01 to 2024-12-31 | 186,728,372 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2024-01-01 to 2024-12-31 | −$52.7m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 12 months, 2024-01-01 to 2024-12-31 | $48.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2024-12-31 | $68.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2024-12-31 | $176.7m | us-gaap:AssetsCurrent |
| Total assets | at 2024-12-31 | $212.7m | us-gaap:Assets |
| Current liabilities | at 2024-12-31 | $8.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2024-12-31 | $11.5m | us-gaap:Liabilities |
| Shareholders' equity | at 2024-12-31 | $201.2m | us-gaap:StockholdersEquity |
| Shares outstanding | at 2024-12-31 | 187,452,495 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1778016/000095017025050344/imab-20241231.htm

Filed Apr 3, 2025.
Source: SEC EDGAR, the filing index for accession 0000950170-25-050344. Last ingested by Listed: Nov 2, 2026, 18:31 ET. No prices; not investment advice.